Royalty Report: Drugs, Disease, Therapeutic – Collection: 329626

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 329626

License Grant
Licensee acquired the exclusive global license to H100â„¢ from Licensor as an asset acquisition.
License Property
H100™ is a topical candidate with at least one active ingredient and potentially a combination of ingredients responsible for the improvement of penile curvature during the acute phase of Peyronie’s disease.
Field of Use
Field of use is for the treatment of acute Peyronie’s disease.

Peyronie’s disease is a condition that occurs upon penile tissue disruption often caused by sexual activity or injury, healing into collagen-based scars that may ultimately harden and cause penile deformity.

IPSCIO Record ID: 2998

License Grant
Licensor grants an exclusive license under the Licensed Technology to research, Develop, use, Commercialize, market, sell and distribute the Product for the Field in the Territory.

Licensor grants a non-exclusive right and license under the Licensed Technology to Manufacture or
have Manufactured the Product for the Field in the Territory.

License Property
Licensor controls certain Patents and Know-How related to the Enzyme and the Product, and has the right to grant certain rights and licenses.

The enzyme is collagenase obtained by fermentation of Clostridium histolyticum, purified by chromatography, lyophilized and substantially free from other proteinases.

The patents include
Methods For Treating Adhesive Capsulitis;
Amelioration Of Dupuytren's Disease;
Methods For Treating Cellulite;
Reduction of Adipose Tissue;
Amelioration of Pcyronie's Disease;
Method of Enhancing the Regeneration of Injured Nerves and Adhesive Pharmaceutical Formulation Therefor;
High Dosage Topical Forms of Collagenasc; and,
Treatment of Duputyren's Disease With Collagenase.

Field of Use
The Field shall mean the prevention or treatment of Dupuytren's Disease, Peyronie's Disease and Adhesive Capsulitis, otherwise known as Frozen Shoulder.

Xiaflex has a distinct mechanism of action. When injected directly into a Dupuytren’s cord, it enzymatically disrupts collagen. As a result of collagen disruption, contracture may be reduced and range of motion may be improved.

Dupuytren's contracture (also called Dupuytren's disease) is an abnormal thickening of the skin in the palm of your hand at the base of your fingers. This thickened area may develop into a hard lump or thick band. Over time, it can cause one or more fingers to curl (contract), or pull sideways or in toward your palm.

Peyronie's (pay-roe-NEEZ) disease is a noncancerous condition resulting from fibrous scar tissue that develops on the penis and causes curved, painful erections. Penises vary in shape and size, and having a curved erection isn't necessarily a cause for concern.

IPSCIO Record ID: 7325

License Grant
In this collaboration agreement the Licensor granted the Licensee exclusive rights to develop and commercialize Xiaflex for the treatment of Dupuytren's contracture and Peyronie's disease in Canada, Australia, Brazil and Mexico upon receipt of the applicable regulatory approvals.

The Licensee was also granted the right of first negotiation to obtain exclusive rights to commercialize any new Xiaflex indications in the Licensee Territory during the term of the Agreement.

License Property
XIAFLEX is a collagenase clostridium histolyticum for the treatment of adult Dupuytren’s contracture (Dupuytren’s) patients with a palpable cord and Peyronie’s disease.

Dupuytren's contracture (also known as morbus Dupuytren, or Dupuytren's disease),[1] is a fixed flexion contracture of the hand due to a palmar fibromatosis,[2] where the fingers bend towards the palm and cannot be fully extended (straightened). It is an inherited proliferative connective tissue disorder which involves the palmar fascia of the hand.
Peyronie's disease or Peyronie disease (/pe?ro?'ni?/), also known as induratio penis plastica (IPP)[1] or chronic inflammation of the tunica albuginea (CITA), is a connective tissue disorder involving the growth of fibrous plaques[2] in the soft tissue of the penis affecting 5% of men.

Field of Use
Peyronie's disease is the development of fibrous scar tissue inside the penis that causes curved, painful erections. Dupuytren's contracture is a hand deformity that usually develops slowly, over years. Dupuytren's contracture affects a layer of tissue that lies under the skin of your palm. Knots of tissue form under the skin – eventually forming a thick cord that can pull one or more of your fingers into a bent position.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.